Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Kezar Life Sciences Inc. (KZR)

12.3   -0.02 (-0.16%) 01-21 18:06
Open: 11.94 Pre. Close: 12.32
High: 12.72 Low: 11.711
Volume: 560,527 Market Cap: 692M
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and autoimmunity. The company was founded in 2015 and is based in South San Francisco, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 12.739 - 12.828 12.828 - 12.896
Low: 11.49 - 11.604 11.604 - 11.692
Close: 12.136 - 12.296 12.296 - 12.42

Technical analysis

as of: 2022-01-21 4:28:03 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 17.70     One year: 20.18
Support: Support1: 11.71    Support2: 9.74
Resistance: Resistance1: 15.15    Resistance2: 17.28
Pivot: 14.05
Moving Average: MA(5): 12.94     MA(20): 14.55
MA(100): 11.10     MA(250): 7.90
MACD: MACD(12,26): -0.34     Signal(9): 0.05
Stochastic oscillator: %K(14,3): 4.60     %D(3): 6.29
RSI: RSI(14): 38.65
52-week: High: 17.28  Low: 4.61  Change(%): 129.9
Average Vol(K): 3-Month: 1645  10-Days: 457

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
KZR has closed above bottom band by 13.9%. Bollinger Bands are 42% wider than normal. The large width of the bands suggest high volatility as compared to Kezar Life Sciences Inc.'s normal range. The bands have been in this wide range for 3 bars. This is a sign that the current trend might continue.

Headline News

Wed, 05 Jan 2022
Is Kezar Life Sciences Inc (KZR) Stock Worth a Buy Wednesday? - InvestorsObserver

Fri, 10 Dec 2021
Kezar Appoints Courtney Wallace to its Board of Directors - Business Wire

Mon, 15 Nov 2021
Kezar Life Sciences Announces Interim Results from the MISSION Phase 2 Trial in Patients with Lupus Nephritis - Yahoo Finance

Wed, 10 Nov 2021
Oxford Finance Provides $50 Million Credit Facility to Kezar Life Sciences, Inc. - Business Wire

Tue, 05 Oct 2021
Kezar Life Sciences Appoints Gitanjali Jain as Vice President, Investor Relations and External Affairs - Business Wire

Mon, 23 Aug 2021
Kezar Life Sciences Announces Completion of Enrollment of Its Phase 2 PRESIDIO Clinical Trial of KZR-616 in Polymyositis and Dermatomyositis - Business Wire

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency n/a
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Underperform Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 56
Shares Float (M) 25
% Held by Insiders 28.84
% Held by Institutions 67.31
Shares Short (K) 3,520
Shares Short P. Month (K) 3,590

Stock Financials

EPS
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 2.460
Profit Margin
Operating Margin
Return on Assets (ttm) -22.1
Return on Equity (ttm) -38.1
Qtrly Rev. Growth
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -0.890
Qtrly Earnings Growth
Operating Cash Flow (M) -41
Levered Free Cash Flow (M) -23

Stock Valuations

PE Ratio -12.30
PEG Ratio
Price to Book value 5.00
Price to Sales
Price to Cash Flow

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.